AXOGEN INC (AXGN)
Health Care · NASDAQ
Axogen is the leading developer and commercializer of technologies for peripheral nerve regeneration and repair.
What AXOGEN INC does
Axogen is the leading developer and commercializer of technologies for peripheral nerve regeneration and repair. The company provides a comprehensive portfolio of FDA-approved solutions including acellular nerve allografts (Avance), nerve protectors and connectors (Axoguard line), and soft tissue matrices (Avive+) that enable surgeons to restore nerve function after traumatic injury, surgical damage, or compression. Products are primarily sold in the U.S. and international markets, with revenue growing 22% YoY as the company expands its nerve repair and protection indications.
Themes: ["Peripheral nerve repair and regeneration","Nerve allografts and biologics","Extracellular matrix (ECM) biomaterials","Surgical reconstruction","Trauma and post-surgical nerve injury","Regulatory risk: Products are subject to FDA oversight and potential regulatory changes; Avive+ Soft Tissue Matrix is under Section 361 PHS Act regulations which are under close FDA scrutiny and subject to potential future regulatory changes.","Reimbursement dependency: Growth dependent on expanded coverage and reimbursement from payers for peripheral nerve injury treatments using synthetic conduits and allografts.","Operating losses: Company is unprofitable with net margin of -13.21%, dependent on continued revenue growth and cash preservation to fund operations.","Axogen develops and commercializes FDA-approved biologic and biomaterial solutions for surgical repair of damaged peripheral nerves, enabling restoration of motor and sensory function after trauma or nerve injury."]
Fundamentals
- Price$43.62 as of 2026-07-09 close
- Market cap$2.3B as of 2026-07-10
- 1-year return+270.9% as of 2026-07-09 close
- Net margin-13.2% as of 2026-07-10
- Gross margin+75.0% as of 2026-07-10
- ROE-20.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+22.4% as of 2026-07-10
- Revenue CAGR (3y)+17.6% SEC XBRL
- Beta1.14 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Integra LifeSciences (IART) — nerve repair and tissue regeneration
- Organogenesis Holdings (ORGO) — regenerative medicine and soft tissue repair
- Arthrex (private) — orthopedic and nerve repair products
- Surgical Biologics manufacturers (synthetic and collagen conduits)
- Surgical biologics and regenerative medicine for peripheral nerve repair
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.